FDA Grants KaloBios Pharmaceuticals Orphan Drug Designation for KB001-A - - BioPharm International

ADVERTISEMENT

FDA Grants KaloBios Pharmaceuticals Orphan Drug Designation for KB001-A



Untitled Document

KaloBios Pharmaceuticals, reported that FDA has granted the company orphan drug designation for KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, for the treatment of cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). KaloBios is currently enrolling patients in a Phase II clinical trial with KB001-A in CF patients chronically infected with Pa. This 180-patient study is intended to evaluate the efficacy and safety of repeat doses of KB001-A. The primary endpoint is time-to-need for antibiotics.

Source: KaloBios Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
FDA Releases REMS Report
September 25, 2014
Author Guidelines

Click here